iXensor Business Summary

iXensor (6734.TWO) is a pioneer in the mobile health (mHealth) sector, specializing in point-of-care testing (POCT) through its proprietary PixoTech platform. The company generates revenue through a diversified model comprising the sale of diagnostic hardware and consumable test strips, technology licensing agreements, and Contract Development and Manufacturing Organization (CDMO) services. Its primary business segments include Women’s Health (Eveline Smart Fertility System), Chronic Disease Management (PixoTest for glucose, HbA1c, and lipid monitoring), and Infectious Diseases (COVID-19 antigen testing). By utilizing smartphone camera optics as a biosensor, iXensor transforms mobile devices into lab-grade diagnostic tools, positioning itself as a high-agility digital health disruptor. In the competitive landscape, iXensor contends with established MedTech giants such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers, as well as specialized players like EKF Diagnostics; it distinguishes itself by offering a seamless, app-integrated data ecosystem that bridges the gap between clinical-grade accuracy and at-home consumer accessibility. The company was founded in 2012 by an interdisciplinary team of Stanford-Taiwan Biomedical Fellowship (STB) alumni, including Dr. Carson Chen, Dr. Jerry Chen, and Dr. Alan Tsai. As of 2026, the leadership team is headed by Dr. Carson Chen, who serves as Chairman and CEO, bringing a background in electrical engineering and medical innovation from MIT and Stanford. Dr. Jerry Chen remains a key figure as Co-founder and Chief Marketing Officer, while Dr. Gabriel Chao leads the technical roadmap as Director of Research and Development. The company’s strategic direction is further bolstered by Board Member and Chief Advisor Dr. Peter Fitzgerald, a Professor Emeritus at Stanford Medical School and a veteran healthcare venture capitalist. iXensor is backed by notable strategic investors, most significantly Rohto Pharmaceutical, and has been accelerated through prestigious global programs including Merck Accelerator and Johnson & Johnson Innovation’s JLABS.